Skip to Content
Merck
All Photos(1)

Key Documents

Y0000808

Sodium phenylbutyrate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-PBA, 4-Phenylbutyric acid, 4-phenylbutyrate, Buphenyl, Sodium 4-phenylbutyrate, TriButyrate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C10H11NaO2
CAS Number:
Molecular Weight:
186.18
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

sodium phenylbutyrate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[Na+].[O-]C(=O)CCCc1ccccc1

InChI

1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1

InChI key

VPZRWNZGLKXFOE-UHFFFAOYSA-M

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sodium phenylbutyrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Sodium phenylbutyrate is a histone deacetylase inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
A F List
Leukemia research, 22 Suppl 1, S7-11 (1998-09-12)
Viola Pomozi et al.
The Journal of investigative dermatology, 134(4), 946-953 (2013-12-20)
Mutations in the ABCC6 gene cause soft-tissue calcification in pseudoxanthoma elasticum (PXE) and, in some patients, generalized arterial calcification of infancy (GACI). PXE is characterized by late onset and progressive mineralization of elastic fibers in dermal, ocular, and cardiovascular tissues.
Sotaro Naoi et al.
The Journal of pediatrics, 164(5), 1219-1227 (2014-02-18)
To examine the effects of 4-phenylbutyrate (4PB) therapy in a patient with progressive familial intrahepatic cholestasis type 2. A homozygous c.3692G>A (p.R1231Q) mutation was identified in ABCB11. In vitro studies showed that this mutation decreased the cell-surface expression of bile
Elisabeth Kemter et al.
The Journal of biological chemistry, 289(15), 10715-10726 (2014-02-26)
Uromodulin (UMOD)-associated kidney disease (UAKD) belongs to the hereditary progressive ER storage diseases caused by maturation defects of mutant UMOD protein. Current treatments of UAKD patients are symptomatic and cannot prevent disease progression. Two in vitro studies reported a positive
Wei Zeng et al.
Life sciences, 103(1), 15-24 (2014-03-22)
Endoplasmic reticulum (ER) stress is involved in the pathogenesis of atherosclerosis (AS). Endothelial cell (EC) dysfunction and monocyte migration to the subendothelium are considered to be essential manifestations of AS. We conducted this study to determine whether ER stress was

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service